Infliximab Drug Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Infliximab Drug Market Overview

Infliximab drugs play a significant role in the management of chronic autoimmune disorders, particularly inflammatory bowel diseases and rheumatic conditions. The growing adoption of biosimilars, increasing demand for targeted biologic therapies, and advancements in subcutaneous formulations are strengthening their clinical utilization across global healthcare systems. The market reached a value of approximately USD 2.94 Billion in 2025, and is anticipated to expand consistently, supported by the growing global burden of autoimmune diseases, broader access to lower-cost biosimilars, and the entry of subcutaneous infliximab formulations that improve patient convenience. Continued investment in clinical evidence by leading manufacturers and growing biosimilar uptake are reinforcing demand. The integration of infliximab into autoimmune disease treatment pathways across rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis is further accelerating market growth globally.

Infliximab Drug Market Segmentation

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Infliximab Drug Market Growth Analysis and Key Influencers

Infliximab Drug Market Dynamics

This section analyzes key factors influencing market growth, including disease burden, regulatory drivers, technology adoption, cost dynamics, and ecosystem shifts.

Infliximab Drug Market Drivers

Rising Biosimilar Innovation and Convenient Biologic Formulations Driving Market Landscape

The market is witnessing steady growth driven by increasing biosimilar adoption, rising autoimmune disease prevalence, and continuous advancements in infliximab biologic formulations. For instance, in March 2026, Celltrion launched the world’s first liquid intravenous infliximab formulation, Remsima IV, across European markets, improving hospital workflow efficiency and reducing drug preparation complexity. The growing demand for cost-effective therapies and simplified administration methods continues to support broader treatment adoption globally. The expanding infliximab biosimilarsindustry is further strengthening commercialization opportunities and competitive product development across healthcare systems during the forecast period.

Infliximab Drug Market Restraints

Brand Drug Patent Erosion and Safety Concerns to Limit the Market Expansion

The infliximab drug market faces notable restraints due to the continued erosion of branded drug revenue following the expiry of key infliximab patents across major markets. Increasing biosimilar competition is exerting significant pricing pressure on branded infliximab products, reducing profit margins for manufacturers and intensifying market competition globally. Additionally, safety concerns associated with TNF-alpha inhibitors, including the risk of serious infections, infusion-related reactions, and rare cases of hepatosplenic T-cell lymphoma, continue to limit treatment adoption among certain patient populations. Ongoing pharmacovigilance requirements, regulatory monitoring, and label update obligations further increase operational and compliance burdens for manufacturers during the forecast period.

Infliximab Drug Market Opportunities

Increasing Availability of Cost-Effective Biosimilars Can Support Future Market Value

The increasing availability of infliximab biosimilars across regulated healthcare markets is expected to support future expansion of the infliximab drug market. For instance, in March 2025, Pfizer Canada announced the commercial launch of IXIFI® (infliximab for injection) in Canada for multiple inflammatory disease indications, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. The growing adoption of cost-effective biosimilars is improving patient access to biologic therapies, optimizing healthcare spending, and strengthening the long-term commercial potential of infliximab-based treatments globally.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Infliximab Drug Market Trends

The market is witnessing several trends, including biosimilar innovation and advanced infliximab formulation development.

Advanced Infliximab Formulation Innovations Are Likely to Enhance Market Growth

The increasing development of advanced infliximab formulations is emerging as a significant trend in the global infliximab drug market, driven by the growing demand for improved treatment convenience, operational efficiency, and patient-centric biologic therapies. For instance, in March 2026, Celltrion announced the European launch of the Remsima IV liquid formulation, designed to reduce preparation complexity and improve storage efficiency across healthcare settings. The innovation is expected to strengthen infliximab adoption and support long-term market growth through enhanced biosimilar competitiveness.

Infliximab Drug Market Share

Rheumatoid Arthritis Segment Likely to Lead the Market by Indication

The rheumatoid arthritis segment is likely to lead the market due to the rising prevalence of chronic autoimmune disorders, increasing biologic treatment adoption, and growing demand for long-term disease management, which continues to support the segment expansion globally. Healthcare providers are increasingly utilizing targeted biologic therapies to improve symptom control, reduce joint damage progression, and enhance patient quality of life. The expanding role of infliximab in rheumatoid arthritis is further contributing to stronger therapeutic adoption across specialty clinics, hospitals, and advanced rheumatology treatment centers during the forecast period.

Infliximab Drug Market Regional Analysis

Among all the regions, North America is likely to lead the market, supported by strong biologics adoption, advanced reimbursement frameworks, and high healthcare expenditure across the region. The presence of major pharmaceutical manufacturers, increasing autoimmune disease burden, and broad access to specialty infusion therapies continue to strengthen regional market expansion. Growing investment in biologic research, specialty care infrastructure, and biosimilar commercialization strategies is also supporting competitive market development. The expanding TNF-alpha inhibitor landscape continues to accelerate biologic treatment utilization across hospitals and specialty treatment facilities.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Leading Players in the Infliximab Drug Market

Key Questions Answered in the Infliximab Drug Market Report

• What was the infliximab drug market value in 2025?
• What is the infliximab drug market forecast outlook for 2026-2035?
• What major factors aid the demand for the infliximab drug market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major infliximab drug market trends?
• Which product type is expected to dominate the market segment?
• Which route of administration is expected to dominate the market segment?
• Which application is expected to dominate the market segment?
• Which distribution channel is expected to dominate the market segment?
• Who are the key players in the infliximab drug market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?